In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice

Involvement of cytotoxic effect on vascular endothelial cells

Ken ichi Ogawara, Keita Un, Ken ichi Tanaka, Kazutaka Higaki, Toshikiro Kimura

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

We evaluated the in vivo anti-tumor effect of polyethylene glycol-modified liposomal doxorubicin (PEG liposomal DOX) in the DOX-resistant Colon-26 cancer cells (C26/DOX)-bearing mice model. IC50 value of DOX to C26/DOX in vitro (40.0 μM) was about 250 times higher than that to control C26 (C26/control) (0.15 μM). However, in vivo anti-tumor effect of PEG liposomal DOX was similar in both C26/control- and C26/DOX-bearing mice, suggesting that the in vivo anti-tumor effect of PEG liposomal DOX was not directly reflecting the sensitivity of these tumor cells to DOX. IC50 value (0.10 μM) of DOX to HUVEC, a model vascular endothelial cell, was similar to that of C26/control. Double immunohistochemical staining of vascular endothelial cells and apoptotic cells within the tumor tissue after intravenous administration of PEG liposomal DOX showed that the extent of co-localization of apoptotic cells with endothelial cells was significantly higher for C26/DOX tumors (60%) than C26/control ones (20%), suggesting that the apoptosis is caused preferentially for vascular endothelial cells in C26/DOX tumor. From these results, it was suggested that the cytotoxic effect of DOX on vascular endothelial cells in the tumor would be involved in the in vivo anti-tumor effect of PEG liposomal DOX in C26/DOX-bearing mice.

Original languageEnglish
Pages (from-to)4-10
Number of pages7
JournalJournal of Controlled Release
Volume133
Issue number1
DOIs
Publication statusPublished - Jan 5 2009

Fingerprint

Doxorubicin
Endothelial Cells
Neoplasms
Inhibitory Concentration 50
liposomal doxorubicin
Intravenous Administration
Colonic Neoplasms
Apoptosis
Staining and Labeling

Keywords

  • Apoptosis
  • Doxorubicin
  • Liposome
  • P-glycoprotein
  • Vascular endothelial cells

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice : Involvement of cytotoxic effect on vascular endothelial cells. / Ogawara, Ken ichi; Un, Keita; Tanaka, Ken ichi; Higaki, Kazutaka; Kimura, Toshikiro.

In: Journal of Controlled Release, Vol. 133, No. 1, 05.01.2009, p. 4-10.

Research output: Contribution to journalArticle

@article{ce66842bd2c8445aa620f7731c686735,
title = "In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells",
abstract = "We evaluated the in vivo anti-tumor effect of polyethylene glycol-modified liposomal doxorubicin (PEG liposomal DOX) in the DOX-resistant Colon-26 cancer cells (C26/DOX)-bearing mice model. IC50 value of DOX to C26/DOX in vitro (40.0 μM) was about 250 times higher than that to control C26 (C26/control) (0.15 μM). However, in vivo anti-tumor effect of PEG liposomal DOX was similar in both C26/control- and C26/DOX-bearing mice, suggesting that the in vivo anti-tumor effect of PEG liposomal DOX was not directly reflecting the sensitivity of these tumor cells to DOX. IC50 value (0.10 μM) of DOX to HUVEC, a model vascular endothelial cell, was similar to that of C26/control. Double immunohistochemical staining of vascular endothelial cells and apoptotic cells within the tumor tissue after intravenous administration of PEG liposomal DOX showed that the extent of co-localization of apoptotic cells with endothelial cells was significantly higher for C26/DOX tumors (60{\%}) than C26/control ones (20{\%}), suggesting that the apoptosis is caused preferentially for vascular endothelial cells in C26/DOX tumor. From these results, it was suggested that the cytotoxic effect of DOX on vascular endothelial cells in the tumor would be involved in the in vivo anti-tumor effect of PEG liposomal DOX in C26/DOX-bearing mice.",
keywords = "Apoptosis, Doxorubicin, Liposome, P-glycoprotein, Vascular endothelial cells",
author = "Ogawara, {Ken ichi} and Keita Un and Tanaka, {Ken ichi} and Kazutaka Higaki and Toshikiro Kimura",
year = "2009",
month = "1",
day = "5",
doi = "10.1016/j.jconrel.2008.09.008",
language = "English",
volume = "133",
pages = "4--10",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice

T2 - Involvement of cytotoxic effect on vascular endothelial cells

AU - Ogawara, Ken ichi

AU - Un, Keita

AU - Tanaka, Ken ichi

AU - Higaki, Kazutaka

AU - Kimura, Toshikiro

PY - 2009/1/5

Y1 - 2009/1/5

N2 - We evaluated the in vivo anti-tumor effect of polyethylene glycol-modified liposomal doxorubicin (PEG liposomal DOX) in the DOX-resistant Colon-26 cancer cells (C26/DOX)-bearing mice model. IC50 value of DOX to C26/DOX in vitro (40.0 μM) was about 250 times higher than that to control C26 (C26/control) (0.15 μM). However, in vivo anti-tumor effect of PEG liposomal DOX was similar in both C26/control- and C26/DOX-bearing mice, suggesting that the in vivo anti-tumor effect of PEG liposomal DOX was not directly reflecting the sensitivity of these tumor cells to DOX. IC50 value (0.10 μM) of DOX to HUVEC, a model vascular endothelial cell, was similar to that of C26/control. Double immunohistochemical staining of vascular endothelial cells and apoptotic cells within the tumor tissue after intravenous administration of PEG liposomal DOX showed that the extent of co-localization of apoptotic cells with endothelial cells was significantly higher for C26/DOX tumors (60%) than C26/control ones (20%), suggesting that the apoptosis is caused preferentially for vascular endothelial cells in C26/DOX tumor. From these results, it was suggested that the cytotoxic effect of DOX on vascular endothelial cells in the tumor would be involved in the in vivo anti-tumor effect of PEG liposomal DOX in C26/DOX-bearing mice.

AB - We evaluated the in vivo anti-tumor effect of polyethylene glycol-modified liposomal doxorubicin (PEG liposomal DOX) in the DOX-resistant Colon-26 cancer cells (C26/DOX)-bearing mice model. IC50 value of DOX to C26/DOX in vitro (40.0 μM) was about 250 times higher than that to control C26 (C26/control) (0.15 μM). However, in vivo anti-tumor effect of PEG liposomal DOX was similar in both C26/control- and C26/DOX-bearing mice, suggesting that the in vivo anti-tumor effect of PEG liposomal DOX was not directly reflecting the sensitivity of these tumor cells to DOX. IC50 value (0.10 μM) of DOX to HUVEC, a model vascular endothelial cell, was similar to that of C26/control. Double immunohistochemical staining of vascular endothelial cells and apoptotic cells within the tumor tissue after intravenous administration of PEG liposomal DOX showed that the extent of co-localization of apoptotic cells with endothelial cells was significantly higher for C26/DOX tumors (60%) than C26/control ones (20%), suggesting that the apoptosis is caused preferentially for vascular endothelial cells in C26/DOX tumor. From these results, it was suggested that the cytotoxic effect of DOX on vascular endothelial cells in the tumor would be involved in the in vivo anti-tumor effect of PEG liposomal DOX in C26/DOX-bearing mice.

KW - Apoptosis

KW - Doxorubicin

KW - Liposome

KW - P-glycoprotein

KW - Vascular endothelial cells

UR - http://www.scopus.com/inward/record.url?scp=57049132040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57049132040&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2008.09.008

DO - 10.1016/j.jconrel.2008.09.008

M3 - Article

VL - 133

SP - 4

EP - 10

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1

ER -